<DOC>
	<DOC>NCT01523782</DOC>
	<brief_summary>There is not clinical validation that the benefits of L-asparaginase can offers during induction chemotherapy for elderly patients, where prevent toxicities is critical.This Phase IIa clinical trial propose to evaluate, specifically for elderly patients, the tolerated dose of GRASPA® in combination with a poly chemotherapy treatment which enables efficient L-asparagine depletion for a period at least equal to 7 days.</brief_summary>
	<brief_title>Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase) in Elderly Patients With First Line Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Aged ≥ 55 years Newly diagnosed ALL without prior treatment Patient capable to receive polychemotherapy (WHO &lt; 2) With or without meningeal disease Signed Informed Consent Forms Subscribed to social security insurance ALL t(9;22) and/or BCRABL positive General state incompatible with chemotherapy treatment (WHO&gt;2) Presenting with a general or visceral contraindication to intensive treatment Patient with another cancer other than ALL Severe evolutive infection, or, HIV seropositive or, active hepatitis related to B or C viral infection Prior treatment with Lasparaginase (irrespective of the form) History of Grade 3 Transfusional incident (life threatening) Presenting rare and/or dangerous antierythrocyte antibodies thus leading to the unavailable of a phenotype compatible Red Blood Cells Included in another clinical trial during the last 4weeks.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Acute Lymphoblastic leukemia</keyword>
	<keyword>Elderly patient</keyword>
	<keyword>Asparaginase</keyword>
</DOC>